Benzenesulfonic acid, 4-C15-16-sec-alkyl derivs.

Endpoint summary

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Justification for type of information:

see read-across document

Reason / purpose for cross-reference:

read-across source

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

ca. 1 470 mg/kg bw

95% CL:

> 1 361 - < 1 588

Mortality:

9 animals in the 1580 and 1990 mg/kg dose died. In the other doses, the number of animals that died were 0 and 3 of 10 for the 1250 and 1415 mg/kg doses, respectively.

Clinical signs:

Within approximately 30 minutes of application, symptoms observed included dry skin, diarrhea, squatting attitude, small dark red eyes, ataxia, hypothermia, diuresis, occasional trembling, tumbling, and prone position.

Gross pathology:

Post mortem sections showed strong hyperemias and swelling, as well as partial damage to the stomach and intestinal mucosae. Also, effects to the stomach, liver, and peritoneum were seen. The tissue sections showed swelling of the gastric mucosa in 3 animals, as well as the growing together of organs of the abdominal cavity with the diaphragm in 2 animals.

Conclusions:

The test material is slightly toxic to rats following acute oral exposure.

Executive summary:

Ten rats per dose (five of each sex) were given oral gavage doses of the test material ranging from 1250 to 1990 mg/kg. The resulting LD50 value was 1470 mg/kg.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

LD50

Value:

1 470 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Justification for type of information:

see read-across document

Reason / purpose for cross-reference:

read-across source

Key result

Sex:

not specified

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Remarks on result:

other: undiluted

Mortality:

No mortality was observed exposure to 2000 mg/kg of the undiluted test material.

Clinical signs:

There were no signs of systemic reaction. Well defined or slight erythema and slight oedema were observed at all test sites after removal of the occlusive dressings. These reactions were unresolved before progressive hardening of the skin was first detected on day 4. All test sites were entirely covered by scab formation from day 7. Sloughing from the scabbed skin began at various times between day 7 and day 12 and was completed before test termination.

Body weight:

Low bodyweight gains or loss of bodyweight were recorded for one male and three female rats on day 8. Two of the same females and a third female rat also showed low bodyweight gains between days 8 and 15.

Gross pathology:

All terminal autopsy findings were normal.

Interpretation of results:

not classified

Remarks:

Migrated information Criteria used for interpretation of results: EU

Conclusions:

The acute lethal dermal dose was found to be greater than 2000 mg/kg.

Executive summary:

The clipped skin on the backs of five male and five female rats were exposed to the test material under an occlusive dressing for 24 hours and observed for another 14 days. Results indicate slight erythema and slight oedema but no acute mortality. The dermal LD50 is > 2000 mg/kg.

Additional information

The acute toxicity of the read-across substance LAB Sulfonic Acid was examined via both the oral (LAB sulfonic Acid) and dermal (LAS, read across) routes of exposure. In the oral exposure study, mortality was seen at the highest dose levels and the resulting acute oral LD50 was 1470 mg LAB Sulfonic Acid/kg. In addition, symptoms observed included dry skin, diarrhea, squatting attitude, small dark red eyes, ataxia, hypothermia, diuresis, occasional trembling, tumbling, and prone position. Post mortem sections showed strong hyperemias and swelling, as well as partial damage to the stomach and intestinal mucosae. Effects to the stomach, liver, and peritoneum were also seen. In the dermal test, no mortality was seen at exposures to 2000 mg LAS/kg. Well defined but slight erythema and slight oedema were observed. According to the CLP guidelines, LAB Sulfonic Acid is a category 4 toxicant based on the oral results (LAB Sulfonic Acid) but is not classified based on dermal results (LAS, read across).